Hangzhou's Sciwind Closes $70 Million Series C for Metabolic Therapies

Sciwind Biosciences, a Hangzhou biopharma focused on metabolic disease, closed a $70 million Series C funding. Sciwind will use the proceeds to advance clinical development of its three leading GLP-1 receptor agonist candidates for NASH and other metabolic conditions. Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutics delivery platforms, which are the basis of its products. The financing round was co-led by IDG Capital, Loyal Valley Capital and LYFE Capital. More details.... Share this with colleagues: // //